New U.S. tariffs on patented pharmaceuticals have limited near-term disruption; China's healthcare sector rebounds strongly this week

Overview

This report is UBS's China healthcare industry weekly note published on April 3, 2026. It focuses on the new U.S. tariff policy on patented pharmaceuticals and their ingredients, one-week performance in the A/H healthcare sector, important events in drug and non-drug areas, and 2025 results and upcoming catalysts for covered companies. The report argues that China's healthcare sector rebounded strongly this week, with H-share biopharma standing out in particular, mainly driven by fund flows, the approaching conference season and the sector's relative immunity amid geopolitical uncertainty.

Core views

The report's core view is that while the new U.S. tariffs on patented pharmaceuticals look headline-grabbing, the actual impact needs to be differentiated by product type, origin, partner agreements and exemption scope. UBS preliminarily believes that Chinese innovative-drug out-licensing assets and some CDMO companies are only modestly affected. On the innovative-drug side, major out-licensed assets such as sac-TMT and SSGJ-707 already have MFN agreements with multinational pharma partners. BeOne's zanubrutinib is expected to face limited impact because the finished product is manufactured in the U.S., the company is domiciled in Switzerland, and the drug has orphan-drug status. On the CDMO side, multinational pharma contracts are likely to be only mildly affected, and some Chinese CDMOs have limited direct exposure to U.S. exports. Meanwhile, drug approvals, clinical progress and pharmaceutical retail data within the sector still provide fundamental signals.

Analysis framework

The report uses a weekly industry tracking framework that combines market performance, policy events, drug approvals and clinical progress, non-drug healthcare events, covered-company results and recent research themes. Its assessment of the tariff policy is based mainly on the tariff schedule, exemption scope, implementation timetable, MFN and localization agreements, pharmaceutical manufacturing and supply-chain arrangements, and the partnership structure between Chinese pharma companies and multinational pharma companies.

Methodology notes

• Policy Impact AnalysisTariff scenario decomposition

  Assess impact by tariff rate, exemptions, agreements and effective date

  The report breaks down the 100% tariff, 15% regional tariff, 0% or 20% agreement-based tariff, generic and orphan-drug exemptions, and the 120/180-day implementation window to judge the actual risk exposure of different drugs and companies.

• Industry Weekly TrackingCombining market performance with event catalysts

  Combine index performance, sub-sector moves, fund flows and industry news

  The report overlays HSHCI, HSBIO, Shenwan Healthcare A/H rankings and sub-sector performance with drug approvals, clinical trials, pharmaceutical retail and medical device events to gauge sector momentum and catalysts.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• BeOne

  A preferred name in the report and discussed in the tariff analysis for zanubrutinib

  Strengths

  The finished product of zanubrutinib is manufactured in the U.S., the company is domiciled in Switzerland, and the drug has orphan-drug designation across all indications, so the report expects limited tariff impact.

  Weaknesses

  The API is not manufactured in the U.S., so tariff details and enforcement interpretation still need to be monitored.

  Comparison

  Compared with companies with higher U.S. export exposure or without exemption conditions, BeOne has stronger policy-risk insulation.

  Risks

  Changes in U.S. tariff rule details, uncertainty over orphan-drug exemption enforcement, and geopolitical escalation.

• WuXi XDC

  A preferred name in the report and a key CRO/CDMO-related company

  Strengths

  Benefiting from rapidly growing antibody-drug conjugate and CRDMO demand, and the report has also recently highlighted its global leadership and healthy CMO conditions.

  Weaknesses

  The CDMO sector may still be affected by cross-border supply-chain scrutiny and customer project timing.

  Comparison

  Compared with traditional CROs, the report places greater emphasis on the resilience of CDMO demand.

  Risks

  Geopolitical tensions, U.S. policy changes, customer order volatility and intensifying industry competition.

• JD Health

  A preferred name in the report, representing online pharmacy and healthcare services

  Strengths

  Benefits from rising online penetration and the framework used to track pharmaceutical retail demand.

  Weaknesses

  Slower-than-expected consumer recovery would affect demand for pharmacy and healthcare services.

  Comparison

  Compared with offline pharmacies, online platforms rely more on user penetration, traffic conversion and the regulatory environment.

  Risks

  Consumer recovery falling short of expectations, tighter regulation of internet healthcare, and intensifying competition in pharmaceutical retail.

• 3SBio

  A preferred name in the report, which also notes that its SSGJ707 is being advanced by Pfizer in a neoadjuvant NSCLC clinical trial

  Strengths

  The clinical progress of SSGJ707 shows the potential for licensing partnerships and global development.

  Weaknesses

  Innovative-drug R&D still faces uncertainty around clinical success rates and commercialization.

  Comparison

  Compared with pharma companies that rely solely on the domestic market, out-licensing projects provide an international catalyst but are also affected by partners' execution pace.

  Risks

  Clinical trial failure, changes in partner development pace, and pressure from drug pricing and reimbursement negotiations.

• Chinese healthcare A/H shares

  The industry asset covered by the report

  Strengths

  Healthcare in A-shares and H-shares rebounded sharply this week, with H-share biopharma standing out and showing relative defensiveness amid policy disruptions.

  Weaknesses

  The industry remains affected by pricing policy, competition, consumer recovery and regulation.

  Comparison

  Healthcare in H-shares outperformed A-shares this week, with biopharma leading among H-share sub-sectors.

  Risks

  Greater-than-expected price cuts from centralized procurement, NRDL negotiation prices below expectations, tighter regulation, and geopolitical escalation.

Key data

• HSHCI/HSBIO weekly gain6.7%/7.6%The statistics cover the period from March 30 to April 3, 2026.
• Shenwan Healthcare A/H weekly gain2.3%/7.1%Ranked 2nd and 1st in the A-share and H-share sectors, respectively.
• H-share biopharmaceutical sub-sector gain10.5%The report says this was mainly driven by fund flows, the approaching conference season and relative defensiveness.
• Proposed tariff on patented pharmaceuticals and ingredients100%Based on the policy announced by the U.S. president on April 2 under Section 232 of the 1962 Trade Expansion Act.
• Tariff rate for some regions15%Applies to drugs from the EU, Japan, South Korea, Switzerland and Liechtenstein; some U.K. products are subject to lower rates.
• Agreement-related tariff0% or 20%Companies that sign both an MFN pricing agreement and a localization agreement are subject to 0%; those that sign only a localization agreement are subject to 20%.
• Implementation window120 days/180 daysEffective after 120 days for some large companies and after 180 days for smaller companies.
• China offline retail pharmacy salesRmb 52.2 billionYear-on-year growth of 1.7% in January 2026, according to Menet.

Impact & implications

From an investment perspective, the report is more inclined to view U.S. drug tariffs as a policy disturbance that requires ongoing monitoring but is manageable in the near term, rather than a systemic negative for China's innovative-drug and CDMO industries. Companies with multinational partners, MFN coverage, U.S.-based finished-product manufacturing, orphan-drug status or lower direct U.S. export exposure may be more resilient. At the sector level, Hong Kong-listed healthcare, especially biopharma, has been strong on fund flows and expectations for the conference season, but investors still need to watch tariff details, implementation scope and corporate supply-chain responses.

Risks

• Greater-than-expected price cuts from GPO projects.
• Intensifying industry competition.
• Prices below expectations after innovative drugs enter NRDL negotiations.
• China's consumer recovery being slower than expected.
• Regulatory announcements and enforcement being stricter than expected.
• An unexpected escalation in geopolitical tensions affecting corporate operations.
• Changes in the details of U.S. patented-pharmaceutical tariffs within the 120/180-day window.

What to watch

• The final details, exemption scope and implementation timetable for U.S. tariffs on patented pharmaceuticals.
• Coverage of multinational pharma companies and their China partnership projects by MFN pricing agreements and localization agreements.
• Regulatory and commercialization progress for key out-licensed or globalized assets such as sac-TMT, SSGJ-707 and zanubrutinib.
• The share of direct U.S. exports for CDMO companies, customer contract stability and new-order trends.
• The catalyst effect of the conference season on sentiment for innovative-drug and biotech stocks.
• NMPA and FDA innovative-drug approval progress, clinical readouts and changes in IND volume.
• China offline retail pharmacy sales, online healthcare penetration and the recovery in consumer healthcare.